Pancreatic Cancer Research

ResearcherThe University of SydneyActive in the last 2 years

Anubhav Mittal

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0003-3960-2968; OpenAlex author ID A5038289205, A5111238598. Sources: OpenAlex.

Their work

Papers
45 (first author 1, last author 11)
Trials
0
Grants
0
Labs led
1
Collaborators
96
Papers, trials and grants by year

2016: 1 paper · 2017: 2 papers · 2018: 2 papers · 2019: 1 paper · 2020: 8 papers · 2021: 6 papers · 2022: 4 papers · 2023: 4 papers · 2024: 4 papers · 2025: 9 papers · 2026: 4 papers

Papers 45

  1. Short-Term Outcomes of Arterial Divestment in Pancreatic Cancer: A Systematic Review and Single Arm Meta-Analysis of Observational Studies. Co-author DOI 10.1002/wjs.70347↗
  2. AI and Epigenetics: A New Opportunity for Early Pancreatic Cancer Detection in Australia. Last author DOI 10.1111/ans.70852↗
  3. Validation of the PANAMA Score in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Distal Pancreatectomy. Last author DOI 10.1111/ans.70999↗
  4. Surgery for Locally Advanced Pancreatic Ductal Adenocarcinoma: Selection of Patients and Surgical Technique. Co-author DOI 10.1159/000550333↗
  5. FXYD3 Is Frequently Expressed in Pancreatic Ductal Adenocarcinoma but Does Not Predict Survival. Last author DOI 10.1002/cam4.70500↗
  6. Stapled Arterial Divestment in Surgery for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1002/jso.28031↗
  7. Overcoming therapy resistance in pancreatic cancer: challenges and emerging strategies. Co-author DOI 10.1016/j.addr.2025.115647↗
  8. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  9. SPAN-C: Results of a Phase II Clinical Trial of Stereotactic Body Radiotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/1754-9485.13874↗
  10. Promising biomarker panel to monitor therapeutic efficacy of neoadjuvant chemotherapy in pancreatic cancer patients. Co-author DOI 10.1111/eci.14341↗
  11. Total lesion glycolysis is a promising predictor of chemo-response in pancreatic cancer patients treated with neoadjuvant chemotherapy prior to surgery. Co-author DOI 10.1111/eci.70046↗
  12. Targeting the NPY/NPY1R signaling axis in mutant p53-dependent pancreatic cancer impairs metastasis. Co-author DOI 10.1126/sciadv.adq4416↗
  13. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  14. Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Arising From Intraductal Papillary Mucinous Neoplasms of the Pancreas. Last author DOI 10.1002/cam4.70499↗
  15. Novel serum protein biomarker panel for early diagnosis of pancreatic cancer. Co-author DOI 10.1002/ijc.34928↗
  16. Artificial Intelligence-based Segmentation of Residual Pancreatic Cancer in Resection Specimens Following Neoadjuvant Treatment (ISGPP-2): International Improv… Co-author DOI 10.1097/pas.0000000000002270↗
  17. Serum and tissue metallome of pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.16124↗
  18. Heterogeneous tumor microenvironment in pancreatic ductal adenocarcinoma: An emerging role of single-cell analysis. Co-author DOI 10.1002/cam4.6407↗
  19. The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer. Co-author DOI 10.1007/s00432-023-05149-4↗
  20. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  21. The Prognostic and Predictive Role of the Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Lymphocyte-to-Monocyte Ratio (LMR) as B… Co-author DOI 10.3390/jcm12051989↗
  22. Clinical suspicion of pancreatic cancer despite negative endoscopic ultrasound-guided fine-needle aspiration biopsy. Co-author DOI 10.1111/ans.17256↗
  23. The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on patients' survival. Co-author DOI 10.1186/s12957-022-02803-y↗
  24. Autophagy: A Key Player in Pancreatic Cancer Progression and a Potential Drug Target. Co-author DOI 10.3390/cancers14143528↗
  25. The Right Treatment Strategy for the Right Patient: A Biomarker-Driven Approach to Neoadjuvant vs. Surgery-First Management of Resectable and Borderline Resect… Last author DOI 10.3390/cancers14153620↗
  26. A unique urinary metabolomic signature for the detection of pancreatic ductal adenocarcinoma. Last author DOI 10.1002/ijc.33368↗
  27. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. Co-author DOI 10.1016/j.ejso.2021.04.005↗
  28. Data independent acquisition of plasma biomarkers of response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.jprot.2020.103998↗
  29. A Critical Assessment of Postneoadjuvant Therapy Pancreatic Cancer Regression Grading Schemes With a Proposal for a Novel Approach. Co-author DOI 10.1097/pas.0000000000001601↗
  30. Real world outcomes of neoadjuvant chemotherapy and radiotherapy for borderline resectable pancreatic cancer: a multicentre observational study. Co-author DOI 10.1111/ans.17151↗
  31. Optimal Upfront Treatment in Surgically Resectable Pancreatic Cancer Candidates: A High-Volume Center Retrospective Analysis. Co-author DOI 10.3390/jcm10122700↗
  32. PSMD11, PTPRM and PTPRB as novel biomarkers of pancreatic cancer progression. Last author DOI 10.1016/j.bbagen.2020.129682↗
  33. Mechanically stressed cancer microenvironment: Role in pancreatic cancer progression. First author DOI 10.1016/j.bbcan.2020.188418↗
  34. International validation and update of the Amsterdam model for prediction of survival after pancreatoduodenectomy for pancreatic cancer. Co-author DOI 10.1016/j.ejso.2019.12.023↗
  35. Tissue biomarker panel as a surrogate marker for squamous subtype of pancreatic cancer. Last author DOI 10.1016/j.ejso.2020.02.001↗
  36. Neoadjuvant therapy for pancreatic cancer changes the composition of the pancreatic parenchyma. Last author DOI 10.1016/j.hpb.2020.03.007↗
  37. Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001472↗
  38. Pancreatoduodenectomy With Arterial Resection for Locally Advanced Pancreatic Cancer of the Head: A Systematic Review. Co-author DOI 10.1097/mpa.0000000000001551↗
  39. Small Molecule KRAS Inhibitors: The Future for Targeted Pancreatic Cancer Therapy? Co-author DOI 10.3390/cancers12051341↗
  40. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. Last author DOI 10.1016/j.ejso.2018.10.050↗
  41. Understanding the Pathophysiology of Psychological Distress and Pancreatic Cancer: A Systematic Review. Co-author DOI 10.1097/mpa.0000000000001016↗
  42. Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data. Co-author DOI 10.1111/ans.13897↗
  43. Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume r… Co-author DOI 10.1016/j.ejso.2017.06.012↗
  44. Circulating and disseminated tumor cells in pancreatic cancer and their role in patient prognosis: a systematic review and meta-analysis. Co-author DOI 10.18632/oncotarget.19928↗
  45. Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.hpb.2016.05.004↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jaswinder Singh Samra · 41 shared papers, 2016–2026 · strength 6.93
  2. Anthony James Gill · 30 shared papers, 2017–2026 · strength 4.61
  3. Sumit Sahni · 20 shared papers, 2020–2025 · strength 3.55
  4. Nick Pavlakis · 18 shared papers, 2017–2026 · strength 2.69
  5. Stephen John Clarke · 13 shared papers, 2017–2026 · strength 1.94
  6. Sarah Maloney · 9 shared papers, 2020–2025 · strength 1.52
  7. Christopher Bahdah Nahm · 12 shared papers, 2017–2025 · strength 1.41
  8. Sooin Byeon · 6 shared papers, 2023–2025 · strength 1.38
  9. Krishna Kotecha · 4 shared papers, 2022–2026 · strength 1.29
  10. Angela S. Y. Chou · 6 shared papers, 2021–2026 · strength 1.15
  11. Josef Gillson · 6 shared papers, 2020–2025 · strength 1.10
  12. George Hruby · 7 shared papers, 2017–2025 · strength 0.87
  13. Taymin du Toit‐Thompson · 3 shared papers, 2023–2025 · strength 0.69
  14. Sanjay Pandanaboyana · 2 shared papers, 2026 · strength 0.68
  15. Malinda Itchins · 6 shared papers, 2017–2023 · strength 0.65
  16. Emily K. Colvin · 4 shared papers, 2019–2023 · strength 0.57
  17. Terence C. Chua · 6 shared papers, 2017–2021 · strength 0.56
  18. Nigel Balfour Jamieson · 5 shared papers, 2019–2023 · strength 0.56
  19. Mark P. Molloy · 3 shared papers, 2020–2024 · strength 0.53
  20. David Lok Hang Chan · 3 shared papers, 2021–2025 · strength 0.50
  21. Hiro Masuda · 2 shared papers, 2022–2026 · strength 0.46
  22. John Albert Windsor · 1 shared paper, 2026 · strength 0.39
  23. Benjamin P. T. Loveday · 1 shared paper, 2026 · strength 0.39
  24. Savio George Barreto · 1 shared paper, 2026 · strength 0.39
  25. Keith John Roberts · 1 shared paper, 2026 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.